Cohance Lifesciences Ltd.

₹307.25

-4.7 (-1.5%)

COHANCE Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 11,781 Cr

P/E Ratio29.2

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	305.9	Bullish
10-DMA	303.1	Bullish
20-DMA	297.54	Bullish
50-DMA	326.88	Bearish
100-DMA	436.95	Bearish
200-DMA	687.94	Bearish

Historical Performance

1 Year

-71.9%

3 Years

-35%

5 Years

-37.4%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	11,976	10,513	13,403	13,202	10,097
Total Expenditure	8,224	6,455	7,662	7,385	5,667
Other Income	586	619	464	924	142
Operating Profit	4,338	4,677	6,205	6,741	4,572
Interest	124	74	128	85	117
Depreciation	775	546	480	391	316
Profit Before Tax	3,439	4,057	5,597	6,676	4,677
Consolidated Net Profit	2,679	3,003	4,113	4,538	3,623
Adjusted EPS	11	12	16	18	14

Compounded Sales Growth

10 Years:26

5 Years:7.5

3 Years:-1.9

TTM:2.6

Compounded Profit Growth

10 Years:19.6

5 Years:-3.3

3 Years:-10

TTM:-2.3

Stock Price CAGR

10 Years:N/A

5 Years:-9

3 Years:-13.1

TTM:-72.7

Return on Equity

10 Years:N/A

5 Years:14.2

3 Years:16.2

last year:10.5

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	255	255	255	255	255
Total Reserves	16,542	20,232	17,097	15,017	11,554
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	8,254	860	718	921	739
Other Current Liabilities	1,960	212	198	295	286
Short Term Borrowings	700	386	646	671	1,056
Total Liabilities	30,312	22,541	21,101	19,668	15,762
Capital Work in Progress	2,548	1,790	1,651	300	961
Long Term Loans & Advances	240	216	92	131	108
Currents Investments	1,917	7,739	4,189	4,812	1,806
Short Term Loans and Advances	1,066	520	2,332	2,060	1,610
Total Current Assets	8,533	12,532	11,554	12,652	6,665
Total Assets	30,312	22,541	21,101	19,668	15,762
Adjusted Book Value	66	80	68	60	46

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 29.2, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -13.1%, indicating poor shareholder returns.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹4338 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹11976 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 273062.6

No. of Shares: 889 (Approx)

Performance:-72.7%

P/L: ₹-726937.4

NIFTY Performance: -2.3%

1 day Top Gainers